-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] According to news on September 29, Dorui Medicine was officially listed on the GEM of the Shenzhen Stock Exchange, with an issue price of 27.
27 yuan per share, and an issue price-earnings ratio of 37.
53 times
.
According to the prospectus, Dorui Medicine is mainly engaged in the research and development, production and sales of chemical preparations and their APIs
.
Since its establishment, the company has focused on the perioperative period and emergency rescue field for product pipeline layout, and has now achieved a strong competitive advantage in the field of plasma substitutes
.
As of the signing date of this listing sponsorship letter, the issuer and its subsidiaries have a total of 7 drug varieties and 16 drug approval numbers, including Sodium Acetate Ringer's Injection, Compound Electrolyte Injection and Compound Mannitol Injection,
etc.
Among them, Sodium Acetate Ringer's Injection is the company's core product, which is mainly used to replenish body fluids, adjust electrolyte balance, and correct acidosis in clinical practice
.
It is reported that the company's sodium acetate Ringer's injection has been included in the medical insurance drug list in 8 provinces including Hebei, Hubei and Jilin
.
From the perspective of R&D level, the company attaches great importance to R&D work.
The existing team has rich R&D experience and profound technical accumulation.
The company has formed a comprehensive R&D personnel structure combining the old and the new
.
As of December 31, 2020, Dorui Medicine has a total of 67 R&D technicians, including 3 core technicians
.
In the past two years, the core technical staff has been stable without major changes
.
At the same time, the company has a new product research and development model that keeps pace with the times, and has successively built a crystal-colloid infusion technology platform, a chiral drug technology platform, The oral sustained and controlled release preparation technology platform has solved the key common technical problems encountered in the process of new product development, effectively shortened the incubation period of similar new products, improved the success rate of new product development, and played a positive role in the enrichment of the company's product pipeline.
the impetus
.
Financial data shows that in 2018, 2019 and 2020, the company's R&D investment was 16.
1962 million yuan, 26.
6488 million yuan, and 23.
3518 million yuan respectively; the operating income in the same period was 348.
8477 million yuan, 449.
4275 million yuan, and 348.
8477 million yuan respectively; R&D investment accounted for The proportion of operating income was 4.
64%, 5.
93% and 4.
76% respectively
.
Tibet Jiakang is the controlling shareholder of the company
.
As of the date of signing the prospectus, Tibet Jiakang held 46,677,966 shares of the company, accounting for 77.
80% of the company's total share capital
.
Deng Yong indirectly controls 77.
80% of the company's shares by holding 64.
00% of the shares of Tibet Jiakang; at the same time, Deng Yong is the executive partner of Tibet Qingchang, and indirectly controls 9.
83% of the company by holding 65.
125% of the property share of Tibet Qingchang shares
.
Therefore, Deng Yong controls 87.
63% of the shares of Tibet Dorui in total and is the actual controller of the company
.
The sponsor of Dorui Medicine's listing is CITIC Securities
.
The company raised 545 million yuan, which will be used for the annual production of 16 million bags of Sodium Acetate Ringer Injection (Phase III) project, new product development project, Tibet headquarters and R&D center construction project, academic promotion and marketing network expansion project, supplementary flow funds
.
Previously, Dorui Medicine stated in the subscription that it will continue to increase investment in research and development of high-end generic drugs in the future, and gradually expand its layout to the field of improved new drugs, adhere to the business ideas of combining generics and innovation, focusing on characteristics, and steady development, focusing on high-tech.
Enriched product pipelines in the field of barrier generic drugs and improved new drugs, continued to improve product competitiveness and patient medication experience, and further increased market share
.
27 yuan per share, and an issue price-earnings ratio of 37.
53 times
.
According to the prospectus, Dorui Medicine is mainly engaged in the research and development, production and sales of chemical preparations and their APIs
.
Since its establishment, the company has focused on the perioperative period and emergency rescue field for product pipeline layout, and has now achieved a strong competitive advantage in the field of plasma substitutes
.
As of the signing date of this listing sponsorship letter, the issuer and its subsidiaries have a total of 7 drug varieties and 16 drug approval numbers, including Sodium Acetate Ringer's Injection, Compound Electrolyte Injection and Compound Mannitol Injection,
etc.
Among them, Sodium Acetate Ringer's Injection is the company's core product, which is mainly used to replenish body fluids, adjust electrolyte balance, and correct acidosis in clinical practice
.
It is reported that the company's sodium acetate Ringer's injection has been included in the medical insurance drug list in 8 provinces including Hebei, Hubei and Jilin
.
From the perspective of R&D level, the company attaches great importance to R&D work.
The existing team has rich R&D experience and profound technical accumulation.
The company has formed a comprehensive R&D personnel structure combining the old and the new
.
As of December 31, 2020, Dorui Medicine has a total of 67 R&D technicians, including 3 core technicians
.
In the past two years, the core technical staff has been stable without major changes
.
At the same time, the company has a new product research and development model that keeps pace with the times, and has successively built a crystal-colloid infusion technology platform, a chiral drug technology platform, The oral sustained and controlled release preparation technology platform has solved the key common technical problems encountered in the process of new product development, effectively shortened the incubation period of similar new products, improved the success rate of new product development, and played a positive role in the enrichment of the company's product pipeline.
the impetus
.
Financial data shows that in 2018, 2019 and 2020, the company's R&D investment was 16.
1962 million yuan, 26.
6488 million yuan, and 23.
3518 million yuan respectively; the operating income in the same period was 348.
8477 million yuan, 449.
4275 million yuan, and 348.
8477 million yuan respectively; R&D investment accounted for The proportion of operating income was 4.
64%, 5.
93% and 4.
76% respectively
.
Tibet Jiakang is the controlling shareholder of the company
.
As of the date of signing the prospectus, Tibet Jiakang held 46,677,966 shares of the company, accounting for 77.
80% of the company's total share capital
.
Deng Yong indirectly controls 77.
80% of the company's shares by holding 64.
00% of the shares of Tibet Jiakang; at the same time, Deng Yong is the executive partner of Tibet Qingchang, and indirectly controls 9.
83% of the company by holding 65.
125% of the property share of Tibet Qingchang shares
.
Therefore, Deng Yong controls 87.
63% of the shares of Tibet Dorui in total and is the actual controller of the company
.
The sponsor of Dorui Medicine's listing is CITIC Securities
.
The company raised 545 million yuan, which will be used for the annual production of 16 million bags of Sodium Acetate Ringer Injection (Phase III) project, new product development project, Tibet headquarters and R&D center construction project, academic promotion and marketing network expansion project, supplementary flow funds
.
Previously, Dorui Medicine stated in the subscription that it will continue to increase investment in research and development of high-end generic drugs in the future, and gradually expand its layout to the field of improved new drugs, adhere to the business ideas of combining generics and innovation, focusing on characteristics, and steady development, focusing on high-tech.
Enriched product pipelines in the field of barrier generic drugs and improved new drugs, continued to improve product competitiveness and patient medication experience, and further increased market share
.
